Skip to main content
Premium Trial:

Request an Annual Quote

Enzo Biochem's Q3 Revenues Drop 13 Percent

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market Monday that its third-quarter revenues fell 13 percent year over year as sales from its clinical lab services and products both declined.

The New York-based life science reagents and diagnostic testing firm reported total revenues of $22.6 million for the three months ended April 30, down from $25.9 million for the third quarter of 2012. Its clinical lab services revenue declined 12 percent year over year to $13.4 million from $15.2 million, while its product revenue fell around 14 percent to $8.3 million from $9.6 million. Its revenue from royalty and license fees dropped to $949,000 from $1.1 million.

Enzo posted a net loss of $5.8 million, or $.15 per share, compared to a net loss of $3.4 million, or $.09 per share, for Q3 2012.

"The fiscal third quarter operating results showed modest sequential improvement," Enzo President Barry Weiner said in a statement. "We believe the launch of a number of new, esoteric tests, which were delayed due to the timing of laboratory inspections and that are now being marketed, will be a catalyst for improved fourth quarter results. This higher margin revenue should help to offset lowered reimbursement rates from Medicare and commercial payers."

Enzo finished the quarter with $5.6 million in cash and cash equivalents and $9.6 million in working capital.

Enzo also announced today that it has arranged an $8 million senior secured revolving line of credit with Healthcare Finance Group that may be increased to $12 million. The firm said that it will use the facility for working capital and growth purposes.

In Tuesday morning trade on the New York Stock Exchange, shares of Enzo were down 6 percent at $2.14.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.